• Please log in or register to access this feature.

Original Article

Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer†

  1. Patrick G. Morris MD1,‡,*,
  2. Gary A. Ulaner MD2,3,
  3. Anne Eaton MS4,
  4. Maurizio Fazio1,5,
  5. Komal Jhaveri MD1,
  6. Sujata Patil PhD4,
  7. Laura Evangelista MD1,6,
  8. Joseph Y. Park BS1,
  9. Cristian Serna-Tamayo1,
  10. Jane Howard1,
  11. Steven Larson MD3,
  12. Clifford A. Hudis MD1,
  13. Heather L. McArthur MD1,
  14. Maxine S. Jochelson MD2

Article first published online: 19 APR 2012

DOI: 10.1002/cncr.27579

Issue

Cancer

Cancer

Volume 118, Issue 22, pages 5454–5462, 15 November 2012

Additional Information

How to Cite

Morris, P. G., Ulaner, G. A., Eaton, A., Fazio, M., Jhaveri, K., Patil, S., Evangelista, L., Park, J. Y., Serna-Tamayo, C., Howard, J., Larson, S., Hudis, C. A., McArthur, H. L. and Jochelson, M. S. (2012), Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer, 118: 5454–5462. doi: 10.1002/cncr.27579

Author Information

  1. 1

    Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York

  3. 3

    Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York

  4. 4

    Department of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

  5. 5

    Division of Molecular Oncology, Vita-Salute San Raffaele University, Milan, Italy

  6. 6

    Veneto Oncology Institute, Scientific Institutes for Recovery and Cure, Milan, Italy

  1. ‡

    Fax: (646) 888-4555

*Breast Cancer Medicine Service, 300 East 66th Street, New York, NY 10065

  1. †

    Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL and at the 2011 American Society of Clinical Oncology Breast Cancer Symposium; September 8-10, 2011; San Francisco, CA.

  2. ‡

    Fax: (646) 888-4555

Publication History

  1. Issue published online: 30 OCT 2012
  2. Article first published online: 19 APR 2012
  3. Manuscript Accepted: 1 MAR 2012
  4. Manuscript Revised: 16 FEB 2012
  5. Manuscript Received: 13 DEC 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (446K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gary A. Ulaner, Gabriella D’Andrea, Hiram S. Cody, Breast Implant Foreign Body Reaction Mimicking Breast Cancer Recurrence on FDG PET/CT, Clinical Nuclear Medicine, 2013, 38, 6, 480

    CrossRef

  2. 2
    Jian Zhang, Zhen Jia, Joseph Ragaz, Ying-Jian Zhang, Min Zhou, Yong-Ping Zhang, Gang Li, Bi-Yun Wang, Zhong-Hua Wang, Xi-Chun Hu, The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer, BMC Cancer, 2013, 13, 1, 42

    CrossRef

  3. 3
    Sheng-Chieh Chan, Cheng-Lung Hsu, Tzu-Chen Yen, Shu-Hang Ng, Chun-Ta Liao, Hung-Ming Wang, The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma, Oral Oncology, 2013, 49, 1, 71

    CrossRef

  4. You have free access to this content4
    Oguz Akin, Sandra B. Brennan, D. David Dershaw, Michelle S. Ginsberg, Marc J. Gollub, Heiko Schöder, David M. Panicek, Hedvig Hricak, Advances in oncologic imaging, CA: A Cancer Journal for Clinicians, 2012, 62, 6
    Direct Link:
  5. 5
    Vincent Vinh-Hung, Hendrik Everaert, Jan Lamote, Mia Voordeckers, Hilde Parijs, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Hansjoerg Vees, Osman Ratib, Georges Vlastos, Mark Ridder, Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer, European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 10, 1618

    CrossRef

View Full Article (HTML) Get PDF (446K)